Drug Trial Radar · NCT05882058
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
204
Planned (sponsor's estimate)
Start
Oct 13, 2023
Primary completion
Dec 17, 2027
Study completion Jun 8, 2028
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- May 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find a suitable dose of BI 764532 (also called obrixtamig) that people with advanced cancer can tolerate. 2 different doses of BI 764532 are tested in this study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. The study has 3 parts. In Part 1, participants are put into 2 groups randomly, which means by chance. Participants have an equal chance of being in either group. One group gets dose 1 of BI 764532 and the other group gets dose 2 of BI 764532. In Part 2 and Part 3, all participants receive the same dose of BI 764532. Part 2 and Part 3 are open to people with a certain kind of tumour called extrapulmonary neuroendocrine carcinoma. All participants receive BI 764532 as an infusion into a vein when starting treatment. If there is benefit for the participants and if they can tolerate it, the treatment is given up to the maximum duration of the study. During this time, participants visit the study site regularly. The total number of visits depends on how they respond to and tolerate the treatment. The first study visits include an overnight stay to monitor participants´ safety. Doctors record any unwanted effects and regularly check the general health of the participants.
Conditions
- Small Cell Lung Carcinoma
- Neuroendocrine Neoplasms
- Extra-pulmonary Neuroendocrine Carcinoma
Interventions
BI 764532, dose 1Drug
BI 764532, dose 1
BI 764532, dose 2Drug
BI 764532, dose 2
Ventana DLL3 RxDx assayDevice
Ventana DLL3 RxDx assay
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Objective response (OR), defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR)Time frame: up to 26 months
- Part 1: Occurrence of treatment-emergent adverse events (TEAEs) during the on-treatment periodTime frame: up to 26 months
- Part 2: Objective response (OR)Time frame: up to 27 months
- Part 3: Occurrence of treatment-emergent adverse events (TEAEs) during the on-treatment periodTime frame: up to 23 months
- Part 3: Objective response (OR) by blinded independent central reviewTime frame: up to 23 months
Locations
59 sites in 12 countries. Site status is shown where the registry gives one.
Infirmary Cancer Care
Mobile, Alabama · Recruiting
Mayo Clinic-Arizona
Phoenix, Arizona · Recruiting
Valkyrie Clinical Trials
Los Angeles, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
Mayo Clinic Cancer Center
Jacksonville, Florida · Recruiting
University of Miami
Miami, Florida · Recruiting
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida · Recruiting
Indiana University
Indianapolis, Indiana · Completed
University of Kansas Cancer Center
Westwood, Kansas · Completed
University of Kentucky Medical Center
Lexington, Kentucky · Recruiting
University of Maryland School of Medicine
Baltimore, Maryland · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Completed
Mayo Clinic, Rochester
Rochester, Minnesota · Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York · Completed
Montefiore Medical Center
The Bronx, New York · Recruiting
Virginia Commonwealth University Health- Adult Outpatient Pavilion
Richmond, Virginia · Recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Multiprofile Hospital For Active Treatment-Uni Hospital Ltd.
Panagyurishte, Bulgaria · Completed
MHAT Heart and brain
Pleven, Bulgaria · Completed
West China Hospital, Sichuan University
Chengdu, China · Recruiting
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
Hangzhou, China · Recruiting
Qilu Hospital, Shangdong University
Jinan, China · Recruiting
960 Hospital of the Chinese People's Liberation Army
Jinan, China · Recruiting
The Second Affiliated Hospital to Nanchang University
Nanchang, China · Recruiting
Shanghai Chest Hospital
Shanghai, China · Recruiting
HOP Intercommunal
Créteil, France · Completed
Hôpital Cochin
Paris, France · Completed
HOP Civil
Strasbourg, France · Completed
Evangelische Lungenklinik Berlin
Berlin, Germany · Completed
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Germany · Recruiting
Universitätsklinikum Erlangen
Erlangen, Germany · Recruiting
Asklepios Fachkliniken München-Gauting
Gauting, Germany · Completed
LungenClinic Grosshansdorf GmbH
Großhansdorf, Germany · Active not recruiting
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Germany · Recruiting
Aichi Cancer Center Hospital
Aichi, Nagoya, Japan · Recruiting
National Cancer Center Hospital East
Chiba, Kashiwa, Japan · Recruiting
Sendai Kousei Hospital
Miyagi, Sendai, Japan · Completed
Osaka International Cancer Institute
Osaka, Osaka, Japan · Recruiting
Kindai University Hospital
Osaka, Sakai, Japan · Recruiting
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.